Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.


Journal Article

Dolastatin-10 is a potent inhibitor of microtubule assembly derived from the sea hare, which displayed significant antitumor activity in preclinical models. We conducted a phase II study of dolastatin-10 in patients with advanced colorectal cancer and no prior chemotherapy for metastatic disease. Fourteen patients received doses ranging from 300 microg/m(2) to 450 microg/m(2) as an intravenous push every 21 days. There were no major objective responses. Toxicity was mainly hematologic, with grade III or IV granulocytopenia occurring in 9 of 42 treatment courses. Other toxic effects were generally mild. Dolastatin-10 lacks clinically significant activity in advanced colorectal cancer when used in this dose and schedule.

Full Text

Duke Authors

Cited Authors

  • Saad, ED; Kraut, EH; Hoff, PM; Moore, DF; Jones, D; Pazdur, R; Abbruzzese, JL

Published Date

  • October 2002

Published In

Volume / Issue

  • 25 / 5

Start / End Page

  • 451 - 453

PubMed ID

  • 12393982

Pubmed Central ID

  • 12393982

International Standard Serial Number (ISSN)

  • 0277-3732

Digital Object Identifier (DOI)

  • 10.1097/00000421-200210000-00005


  • eng

Conference Location

  • United States